As of Feb 12
| +4.95 / +5.93%|
The 21 analysts offering 12-month price forecasts for Valeant Pharmaceuticals have a median target of 155.00, with a high estimate of 213.00 and a low estimate of 90.00. The median estimate represents a +75.36% increase from the last price of 88.39.
The current consensus among 23 polled investment analysts is to Buy stock in Valeant Pharmaceuticals. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.